NCT01627561View on ClinicalTrials.gov

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

October 15, 2012

Primary Completion Date

April 23, 2014

Study Completion Date

October 6, 2016

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Cervarix

2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.

BIOLOGICAL

Priorix

1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.

BIOLOGICAL

Infanrix

1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.

Trial Locations (4)

38007

GSK Investigational Site, Bogotá

Unknown

GSK Investigational Site, Yopal, Casanare

GSK Investigational Site, Panama City

04530

GSK Investigational Site, México

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01627561 - Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old | Biotech Hunter | Biotech Hunter